|
1
|
Martínez-Rodríguez F, Limones-González JE,
Mendoza-Almanza B, Esparza-Ibarra EL, Gallegos-Flores PI,
Ayala-Luján JL, Ayala-Luján JL, Godina-González S, Salinas E and
Mendoza-Almanza G: Understanding cervical cancer through
proteomics. Cells. 10:18542021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Revathidevi S, Murugan AK, Nakaoka H,
Inoue I and Munirajan AK: APOBEC: A molecular driver in cervical
cancer pathogenesis. Cancer Lett. 496:104–116. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yamashita H, Kawasawa YI, Shuman L, Zheng
Z, Tran T, Walter V, Warrick JI, Chen G, Al-Ahmadie H, Kaag M, et
al: Repression of transcription factor AP-2 alpha by PPARγ reveals
a novel transcriptional circuit in basal-squamous bladder cancer.
Oncogenesis. 8:692019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wu J: Pancreatic cancer-derived exosomes
promote the proliferation, invasion, and metastasis of pancreatic
cancer by the miR-3960/TFAP2A Axis. J Oncol. 2022:35903262022.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cao L, Wang S, Zhang Y, Wong KC, Nakatsu
G, Wang X, Wong S, Ji J and Yu J: Zinc-finger protein 471
suppresses gastric cancer through transcriptionally repressing
downstream oncogenic PLS3 and TFAP2A. Oncogene. 37:3601–3616. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Guoren Z, Zhaohui F, Wei Z, Mei W, Yuan W,
Lin S, Xiaoyue X, Xiaomei Z and Bo S: TFAP2A Induced ITPKA Serves
as an oncogene and interacts with DBN1 in lung adenocarcinoma. Int
J Biol Sci. 16:504–514. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shi D, Xie F, Zhang Y, Tian Y, Chen W, Fu
L, Wang J, Guo W, Kang T, Huang W and Deng W: TFAP2A regulates
nasopharyngeal carcinoma growth and survival by targeting HIF-1α
signaling pathway. Cancer Prev Res (Phila). 7:266–277. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xu H, Wang L and Jiang X: Silencing of
lncRNA DLEU1 inhibits tumorigenesis of ovarian cancer via
regulating miR-429/TFAP2A axis. Mol Cell Biochem. 476:1051–1061.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen S, Li H, Li X, Chen W, Zhang X, Yang
Z, Chen Z, Chen J, Zhang Y, Shi D and Song M: High SOX8 expression
promotes tumor growth and predicts poor prognosis through GOLPH3
signaling in tongue squamous cell carcinoma. Cancer Med.
9:4274–4289. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yuanhua L, Pudong Q, Wei Z, Yuan W, Delin
L, Yan Z, Geyu L and Bo S: TFAP2A Induced KRT16 as an oncogene in
lung adenocarcinoma via EMT. Int J Biol Sci. 15:1419–1428. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xiong Y, Feng Y, Zhao J, Lei J, Qiao T,
Zhou Y, Lu Q, Jiang T, Jia L and Han Y: TFAP2A potentiates lung
adenocarcinoma metastasis by a novel miR-16
family/TFAP2A/PSG9/TGF-β signaling pathway. Cell Death Dis.
12:3522021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liang Y, Cheng G, Huang D and Yuan F:
Linc00467 promotes invasion and inhibits apoptosis of head and neck
squamous cell carcinoma by regulating miR-1285-3p/TFAP2A. Am J
Transl Res. 13:6248–6259. 2021.PubMed/NCBI
|
|
14
|
Hao H, Xiao D, Pan J, Qu J, Egger M,
Waigel S, Sanders MA, Zacharias W, Rai SN and McMasters KM:
Sentinel lymph node genes to predict prognosis in node-positive
melanoma patients. Ann Surg Oncol. 24:108–116. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pu M, Li C, Qi X, Chen J, Wang Y, Gao L,
Miao L and Ren J: MiR-1254 suppresses HO-1 expression through seed
region-dependent silencing and non-seed interaction with TFAP2A
transcript to attenuate NSCLC growth. PLoS Genet. 13:e10068962017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brody R, Zhang Y, Ballas M, Siddiqui MK,
Gupta P, Barker C, Midha A and Walker J: PD-L1 expression in
advanced NSCLC: Insights into risk stratification and treatment
selection from a systematic literature review. Lung Cancer.
112:200–215. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jiang Y, Chen M, Nie H and Yuan Y: PD-1
and PD-L1 in cancer immunotherapy: Clinical implications and future
considerations. Hum Vaccin Immunother. 15:1111–1122. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wei F, Zhang T, Deng SC, Wei JC, Yang P,
Wang Q, Chen ZP, Li WL, Chen HC, Hu H and Cao J: PD-L1 promotes
colorectal cancer stem cell expansion by activating HMGA1-dependent
signaling pathways. Cancer Lett. 450:1–13. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Darvin P, Toor SM, Sasidharan Nair V and
Elkord E: Immune checkpoint inhibitors: Recent progress and
potential biomarkers. Exp Mol Med. 50:1–11. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Frenel JS, Le Tourneau C, O'Neil B, Ott
PA, Piha-Paul SA, Gomez-Roca C, van Brummelen EMJ, Rugo HS, Thomas
S, Saraf S, et al: Safety and efficacy of pembrolizumab in
advanced, programmed death ligand 1-positive cervical cancer:
Results From the Phase Ib KEYNOTE-028 Trial. J Clin Oncol.
35:4035–4041. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sun C, Mezzadra R and Schumacher TN:
Regulation and Function of the PD-L1 Checkpoint. Immunity.
48:434–452. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Orso F, Corà D, Ubezio B, Provero P,
Caselle M and Taverna D: Identification of functional TFAP2A and
SP1 binding sites in new TFAP2A-modulated genes. BMC Genomics.
11:3552010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tchieu J, Zimmer B, Fattahi F, Amin S,
Zeltner N, Chen S and Studer L: A modular platform for
differentiation of human PSCs into all major ectodermal lineages.
Cell Stem Cell. 21:399–410.e7. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
White JR, Thompson DT, Koch KE, Kiriazov
BS, Beck AC, van der Heide DM, Grimm BG, Kulak MV and Weigel RJ:
AP-2α-Mediated Activation of E2F and EZH2 drives melanoma
metastasis. Cancer Res. 81:4455–4470. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bennett KL, Romigh T and Eng C: AP-2alpha
induces epigenetic silencing of tumor suppressive genes and
microsatellite instability in head and neck squamous cell
carcinoma. PLoS One. 4:e69312009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kagohara LT, Zamuner F, Davis-Marcisak EF,
Sharma G, Considine M, Allen J, Yegnasubramanian S, Gaykalova DA
and Fertig EJ: Integrated single-cell and bulk gene expression and
ATAC-seq reveals heterogeneity and early changes in pathways
associated with resistance to cetuximab in HNSCC-sensitive cell
lines. Br J Cancer. 123:101–113. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhu JL, Xue WB, Jiang ZB, Feng W, Liu YC,
Nie XY and Jin LY: Long noncoding RNA CDKN2B-AS1 silencing protects
against esophageal cancer cell invasion and migration by
inactivating the TFAP2A/FSCN1 axis. Kaohsiung J Med Sci.
38:1144–1154. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Huang HX, Yang G, Yang Y, Yan J, Tang XY
and Pan Q: TFAP2A is a novel regulator that modulates ferroptosis
in gallbladder carcinoma cells via the Nrf2 signalling axis. Eur
Rev Med Pharmacol Sci. 24:4745–4755. 2020.PubMed/NCBI
|
|
30
|
Kołat D, Kałuzińska Ż, Bednarek AK and
Płuciennik E: The biological characteristics of transcription
factors AP-2α and AP-2γ and their importance in various types of
cancers. Biosci Rep. 39:BSR201819282019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fan L, Liu Z, Zhang Y, Zhu H, Yu H, Yang
F, Yang R and Wu F: MiRNA373 induces cervical squamous cell
carcinoma SiHa cell apoptosis. Cancer Biomark. 21:455–460. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang Ll, Lu J, Liu RQ, Hu MJ, Zhao YM,
Tan S, Wang SY, Zhang B, Nie W, Dong Y, et al: Chromatin
accessibility analysis reveals that TFAP2A promotes angiogenesis in
acquired resistance to anlotinib in lung cancer cells. Acta
Pharmacol Sin. 41:1357–1365. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wei CW, Lin CC, Yu YL, Lin CY, Lin PC, Wu
MT, Chen CJ, Chang W, Lin SZ, Chen YL and Harn HJ:
n-Butylidenephthalide induced apoptosis in the A549 human lung
adenocarcinoma cell line by coupled down-regulation of AP-2alpha
and telomerase activity. Acta Pharmacol Sin. 30:1297–1306. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yang K, Niu Y, Cui Z, Jin L, Peng S and
Dong Z: Long noncoding RNA TFAP2A-AS1 promotes oral squamous cell
carcinoma cell growth and movement via competitively binding
miR-1297 and regulating TFAP2A expression. Mol Carcinog.
61:865–875. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xu J, Zheng J, Wang J and Shao J:
miR-876-5p suppresses breast cancer progression through targeting
TFAP2A. Exp Ther Med. 18:1458–1464. 2019.PubMed/NCBI
|
|
36
|
Kluger HM, Zito CR, Turcu G, Baine MK,
Zhang H, Adeniran A, Sznol M, Rimm DL, Kluger Y, Chen L, et al:
PD-L1 studies across tumor types, its differential expression and
predictive value in patients treated with immune checkpoint
inhibitors. Clin Cancer Res. 23:4270–4279. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Enwere EK, Kornaga EN, Dean M, Koulis TA,
Phan T, Kalantarian M, Köbel M, Ghatage P, Magliocco AM,
Lees-Miller SP and Doll CM: Expression of PD-L1 and presence of
CD8-positive T cells in pre-treatment specimens of locally advanced
cervical cancer. Mod Pathol. 30:577–586. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Meng Y, Liang H, Hu J, Liu S, Hao X, Wong
MSK, Li X and Hu L: PD-L1 expression correlates with tumor
infiltrating lymphocytes and response to neoadjuvant chemotherapy
in cervical cancer. J Cancer. 9:2938–2945. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mezache L, Paniccia B, Nyinawabera A and
Nuovo GJ: Enhanced expression of PD L1 in cervical intraepithelial
neoplasia and cervical cancers. Mod Pathol. 28:1594–1602. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Huang RSP, Haberberger J, Murugesan K,
Danziger N, Hiemenz M, Severson E, Duncan DL, Ramkissoon SH, Ross
JS, Elvin JA and Lin DI: Clinicopathologic and genomic
characterization of PD-L1-positive uterine cervical carcinoma. Mod
Pathol. 34:1425–1433. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yang W, Lu YP, Yang YZ, Kang JR, Jin YD
and Wang HW: Expressions of programmed death (PD)-1 and PD-1 ligand
(PD-L1) in cervical intraepithelial neoplasia and cervical squamous
cell carcinomas are of prognostic value and associated with human
papillomavirus status. J Obstet Gynaecol Res. 43:1602–1612. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hsu PC, Li SH and Yang CT: Recurrent
Pneumonitis Induced by Atezolizumab (Anti-Programmed Death Ligand
1) in NSCLC patients who previously experienced anti-programmed
death 1 immunotherapy-related pneumonitis. J Thorac Oncol.
13:e227–e230. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Heeren AM, Punt S, Bleeker MC,
Gaarenstroom KN, van der Velden J, Kenter GG, de Gruijl TD and
Jordanova ES: Prognostic effect of different PD-L1 expression
patterns in squamous cell carcinoma and adenocarcinoma of the
cervix. Mod Pathol. 29:753–763. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Karim R, Jordanova ES, Piersma SJ, Kenter
GG, Chen L, Boer JM, Melief CJ and van der Burg SH: Tumor-expressed
B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and
survival of patients with cervical carcinoma. Clin Cancer Res.
15:6341–6347. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lambert SA, Jolma A, Campitelli LF, Das
PK, Yin Y, Albu M, Chen X, Taipale J, Hughes TR and Weirauch MT:
The human transcription factors. Cell. 172:650–665. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wankhade S, Yu Y, Weinberg J, Tainsky MA
and Kannan P: Characterization of the activation domains of AP-2
family transcription factors. J Biol Chem. 275:29701–29708. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hou J, Zhao R, Xia W, Chang CW, You Y, Hsu
JM, Nie L, Chen Y, Wang YC, Liu C, et al: PD-L1-mediated gasdermin
C expression switches apoptosis to pyroptosis in cancer cells and
facilitates tumour necrosis. Nat Cell Biol. 22:1264–1275. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Du W, Zhu J, Zeng Y, Liu T, Zhang Y, Cai
T, Fu Y, Zhang W, Zhang R, Liu Z and Huang JA: KPNB1-mediated
nuclear translocation of PD-L1 promotes non-small cell lung cancer
cell proliferation via the Gas6/MerTK signaling pathway. Cell Death
Differ. 28:1284–1300. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Clark CA, Gupta HB, Sareddy G, Pandeswara
S, Lao S, Yuan B, Drerup JM, Padron A, Conejo-Garcia J, Murthy K,
et al: Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth,
Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma. Cancer
Res. 76:6964–6974. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wang S, Li J, Xie J, Liu F, Duan Y, Wu Y,
Huang S, He X, Wang Z and Wu X: Programmed death ligand 1 promotes
lymph node metastasis and glucose metabolism in cervical cancer by
activating integrin β4/SNAI1/SIRT3 signaling pathway. Oncogene.
37:4164–4180. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Cao D, Qi Z, Pang Y, Li H, Xie H, Wu J,
Huang Y, Zhu Y, Shen Y, Zhu Y, et al: Retinoic acid-related orphan
receptor C regulates proliferation, glycolysis, and chemoresistance
via the PD-L1/ITGB6/STAT3 signaling axis in bladder cancer. Cancer
Res. 79:2604–2618. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wang F, Yang L, Xiao M, Zhang Z, Shen J,
Anuchapreeda S, Tima S, Chiampanichayakul S and Xiao Z: PD-L1
regulates cell proliferation and apoptosis in acute myeloid
leukemia by activating PI3K-AKT signaling pathway. Sci Rep.
12:114442022. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Beck AC, Cho E, White JR, Paemka L, Li T,
Gu VW, Thompson DT, Koch KE, Franke C, Gosse M, et al: AP-2α
Regulates S-Phase and is a marker for sensitivity to PI3K inhibitor
buparlisib in colon cancer. Mol Cancer Res. 19:1156–1167. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zhang L, Zhao Y, Tu Q, Xue X, Zhu X and
Zhao KN: The roles of programmed cell death ligand-1/programmed
cell death-1 (PD-L1/PD-1) in HPV-induced cervical cancer and
potential for their use in blockade therapy. Curr Med Chem.
28:893–909. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Royer HD, Freyaldenhoven MP, Napierski I,
Spitkovsky DD, Bauknecht T and Dathan N: Delineation of human
papillomavirus type 18 enhancer binding proteins: The intracellular
distribution of a novel octamer binding protein p92 is cell cycle
regulated. Nucleic Acids Res. 19:2363–2371. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Turek LP: The structure, function, and
regulation of papillomaviral genes in infection and cervical
cancer. Adv Virus Res. 44:305–356. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Parker JN, Zhao W, Askins KJ, Broker TR
and Chow LT: Mutational analyses of differentiation-dependent human
papillomavirus type 18 enhancer elements in epithelial raft
cultures of neonatal foreskin keratinocytes. Cell Growth Differ.
8:751–762. 1997.PubMed/NCBI
|
|
58
|
Zhao W, Chow LT and Broker TR: A distal
element in the HPV-11 upstream regulatory region contributes to
promoter repression in basal keratinocytes in squamous epithelium.
Virology. 253:219–229. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Beger M, Butz K, Denk C, Williams T, Hurst
HC and Hoppe-Seyler F: Expression pattern of AP-2 transcription
factors in cervical cancer cells and analysis of their influence on
human papillomavirus oncogene transcription. J Mol Med (Berl).
79:314–320. 2001. View Article : Google Scholar : PubMed/NCBI
|
